OBN (UK) Ltd

Free-to-use software version available for academic and non-profit researchers worldwide Intuitive system provides robust data management tools to support scientific collaboration and engagement with funding bodies through streamlined adherence to FAIR data principles Silverstone, UK, 11 March 2026: Lab Thread Ltd, a UK‐based life science software company, today announced the release of a free of charge version of the Company’s Unified Lab Software Platform, available to academic and...

BOSTON, MA and LONDON, UK – March 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Syntis Bio, Inc. and is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO). Syntis Bio is a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine to treat obesity and rare metabolic diseases.

London, UK, 10 Mar 2026 – C-Further, an international consortium committed to creating new therapeutics for childhood cancers, today unveils the first early-stage therapeutic programmes for its pipeline, dedicated to paediatric oncology indications. Through its collaborative model, C-Further has partnered with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham to advance CF-012 for the potential treatment of Ewing sarcoma.

Sandwich, UK – 9 March 2026: SignaCor Therapeutics has been named the winner of Discovery Park’s startup growth programme for innovations in cardiovascular health, securing £250k in funding from venture capital firm Zinc. This investment forms part of a £1M seed round expected to close in April. Northern Ireland-based SignaCor is developing medicines for hypertrophic cardiomyopathy, where thickening of the heart muscle makes it harder for blood to be pumped around the body.

Upperton has submitted its application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the approval of its new 7,000 sq. ft sterile manufacturing facility. The submission follows the successful execution of multiple aseptic process simulations (APS media-fill batches), completed in accordance with the revised EU GMP Annex 1 (2023) requirements. The sterile facility is in addition to Upperton’s existing 50,000 sq.

LONDON, UK and BRUSSELS, Belgium – March 5, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Evondos Group and is pleased to announce the placement of Tom Ellison as Chief Financial Officer (CFO). Evondos Group is the leading provider of automated medicine dispensing services in northern Europe.

PHILADELPHIA, PA – February 26, 2026 – Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

For much of the past decade, success in medical devices, life sciences, and biotechnology has been defined by scientific excellence. Strong R&D teams, breakthrough IP, and regulatory progress were the primary currencies of growth. Today, that equation has changed. Across the UK, Europe, and the US, SMEs continue to face funding and technology challenges, but many are now discovering that securing the right commercial talent can be just as difficult — and just as limiting to growth.

Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team. With more than 25 years’ experience as a pharmaceutical physician specialising in early development oncology, haemato-oncology, clinical pharmacology and ATMPs, Kate began her career training as an anaesthetist before working for a CRO. She then spent 16 years at AstraZeneca where she worked as Medicine and Science Director.

Ashdown Forest, East Sussex – As organisations grapple with digital overload, hybrid fragmentation and rising complexity, Thorp Coaching today launches a distinctive leadership and conservation experience on private protected land at Pippingford Estate, in the heart of East Sussex’s Ashdown Forest. The programme responds to a modern leadership tension: teams are constantly connected yet increasingly stretched, while leaders face mounting pressure to innovate in a volatile commercial landscape.